← All diseases Cancer

Chronic lymphocytic leukemia

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchStrongest evidence only (63)Meta-analysis (7)Treatment guideline (3)Phase 3 study (32)Systematic review (13)Randomized trial (8)Clinical trial (588)Review article (208)Early study (phase 1 or 2) (38)Case report (197)Laboratory or animal study (14)Commentary or editorial (62)Retracted publication (2) Studies currently seeking participants only (43)

Filter

Publications and studies (1769)

• A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. (2026/12/01) ♡
  Read in plain language
• Allogeneic Stem Cell Transplantation-A Salvage Option for High-Risk Chronic Lymphocytic Leukemia Patients: A 15-Year Single-Center Experience. (2026/09/01) ♡
  Read in plain language
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Studying Chronic Lymphocytic Leukemia Microenvironment in the Multi Omics Era. (2026/09/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. BTK inhibitors are associated with a lower risk of myeloid neoplasms and non-melanoma skin cancer compared with chemoimmunotherapy in chronic lymphocytic leukemia: a propensity score-matched analysis. (2026/08/10) ♡
• Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia - real-world analysis of Polish adult leukemia study group. (2026/08/10) ♡
• Prognostic significance of baseline liver enzyme patterns in chronic lymphocytic leukemia: a nationwide real-world cohort study. (2026/08/09) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clonal dynamics on the road to hematological malignancy (MBL, MGUS, CH). (2026/08/09) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia. (2026/08/07) ♡
• Correction to "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation". (2026/08/07) ♡
• Treatment of Cold Agglutinin Syndrome Secondary to Chronic Lymphocytic Leukemia With Sutimlimab and Obinutuzumab-Venetoclax. (2026/08/07) ♡
• Association between serum biomarkers and clinical stage in treatment-naïve chronic lymphocytic leukemia. (2026/08/06) ♡
• Causal Inference Approaches to Estimating the Effect of Ibrutinib Dose Modifications on Progression-Free Survival in Chronic Lymphocytic Leukemia. (2026/08/06) ♡
• The Unusual Coexistence of Chronic Lymphocytic Leukemia, Dengue Fever, and Acute Kidney Injury: A Case Report. (2026/08/06) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Navigating the Paradigm Shift in Chronic Lymphocytic Leukemia: Insights From EHA 2026. (2026/08/05) ♡
• Cerebral aspergillosis under ibrutinib therapy: clinical features and management challenges. (2026/08/04) ♡
• The BTK inhibitor acalabrutinib inhibits the expression of PD-L1 on myeloid cells during inflammation. (2026/08/04) ♡
• The significance of galectin-9 and T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) in patients with chronic lymphocytic leukemia: The role of immune evasion. (2026/08/01) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial. (2026/08/01) ♡
• Beyond MURANO: sequencing therapy in relapsed chronic lymphocytic leukaemia. (2026/08/01) ♡
• First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy Regimens. (2026/08/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL Management. (2026/08/01) ♡
• Regional Standardization of CLL Management: Results of a Delphi Consensus Process. (2026/08/01) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Acute and Chronic Leukemia in Sub-Saharan Africa: A Systematic Review. (2026/08/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clinical characterization of cutaneous mucormycosis in patients receiving Bruton tyrosine kinase inhibitor therapy with Ibrutinib: A new case report and comparative discussion. (2026/08/01) ♡
• HS1 loss drives cytoskeletal dysregulation and reduces sensitivity to BTK inhibition in chronic lymphocytic leukemia. (2026/07/31) ♡
• Altered expression of ET-1 and HMGB1 together with higher MMP-9 activity in serum-derived exosomes of chronic lymphocytic leukemia. (2026/07/31) ♡
• Infection Incidence and Survival in Patients With Multiple Myeloma and Chronic Lymphocytic Leukaemia: A Growing Concern in the Era of Modern Therapies. (2026/07/31) ♡
• Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States. (2026/07/30) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Bruton tyrosine kinase inhibitors and cardiovascular adverse events. (2026/07/30) ♡
• Resolution of Paraneoplastic Cutaneous Angioendotheliomatosis After CAR T-Cell Therapy in TP53-Deleted CLL: A Case Report. (2026/07/30) ♡
• Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004. (2026/07/28) ♡
• Rab GTPases drive ligand-independent NOTCH1 activation via altered endocytic trafficking in chronic lymphocytic leukemia. (2026/07/28) ♡
• Reduced colony-stimulating factor 1 receptor expression in myeloid cells has limited impact on chronic lymphocytic leukaemia progression. (2026/07/26) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Therapeutic potential of antisense oligonucleotides in hematological malignancies. (2026/07/25) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Vitreoretinal lymphoma revealing Richter transformation. (2026/07/25) ♡
• Cancer-Associated BCL-2 Mutants Reveal Mechanisms Towards Venetoclax Resistance. (2026/07/24) ♡
• Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia. (2026/07/24) ♡
• Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors. (2026/07/22) ♡
• Co-occurrence of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Head and Neck Squamous Cell Carcinoma: A Single-Institution Study. (2026/07/22) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Surrogate Endpoints in CLL: From Promise and Pitfalls to a Context-Specific Validation Framework. (2026/07/21) ♡
• Impact of high-fat Western diet on chronic lymphocytic leukemia disease progression and gut microbiome profile in Eµ-TCL1 mice. (2026/07/21) ♡
• Correction: A new approach for elimination of apoptotic resistance caused by MDM2/MDMX amplification in chronic lymphocytic leukemia: combination of ALRN-6924 and radiofrequency exposure. (2026/07/20) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Boric Acid Combined with Venetoclax Induces Apoptosis in CLL Cell Lines via Caspase Activation and Oxidative Stress Modulation: In Vitro and In Silico Study. (2026/07/20) ♡
• Lessons for the Clinical Nephrologist: paraneoplastic cryoglobulinemic glomerulopathy as a manifestation of chronic lymphocytic leukemia. (2026/07/20) ♡
• Collision Tumor of Merkel Cell Carcinoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Cytological and Flow Cytometric Diagnostic Pitfall. (2026/07/20) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. CaMKK2 Expression Correlates with High-Risk CLL Biology, and Pharmacologic Inhibition Is Associated with Reduced Leukemic Cell Survival and Nurse-like Cell Support In Vitro. (2026/07/20) ♡
• Infectious adverse events associated with novel Bruton tyrosine kinase (BTK) inhibitors in adults with chronic lymphocytic leukaemia: A meta-analysis of randomized controlled trials. (2026/07/17) ♡
• Covalent Bruton's tyrosine kinase inhibitor HZ-A-018 in patients with relapsed or refractory B cell malignancies: A multicenter phase I study. (2026/07/17) ♡
• Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts. (2026/07/16) ♡
• Recurrent Granulomatous Panuveitis and Sarcoidosis-Like Reaction Associated with Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Recurrence After Switching from Ibrutinib to Pirtobrutinib. (2026/07/16) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.